论文部分内容阅读
目的探讨孟鲁司特联合吸入糖皮质激素治疗小儿慢性中度持续支气管哮喘的临床疗效。方法随机选取广东省乐昌市第二人民医院2014年12月至2017年1月收治的70例慢性中度持续支气管哮喘患儿,随机分为对照组和观察组,每组35例。其中对照组采用吸入布地奈德治疗,观察组采用孟鲁司特联合吸入糖皮质激素治疗,比较两组患儿治疗3个月后的临床治疗效果。结果两组治疗前半胱氨酰白三烯(Cys LTs)和白细胞介素-5(IL-5)水平比较差异无统计学意义(P>0.05);治疗后观察组各指标明显低于对照组(P<0.05),观察组发作时间及发作次数均明显低于对照组(P<0.05)。两组治疗前咳嗽、日间症状、夜间症状评分比较差异无统计学意义(P>0.05),治疗后观察组显著低于对照组(P<0.05)。结论针对慢性中度持续支气管哮喘的治疗,采用孟鲁司特联合吸入糖皮质激素治疗效果显著,能够使患儿的临床症状得到有效改善,对患儿的恢复有着促进作用。
Objective To investigate the clinical efficacy of montelukast combined inhaled corticosteroids in the treatment of children with chronic moderate persistent bronchial asthma. Methods Seventy patients with chronic moderate persistent bronchial asthma admitted to the Second People’s Hospital of Lechang City, Guangdong Province from December 2014 to January 2017 were randomly divided into control group and observation group with 35 cases in each group. The control group was treated with inhaled budesonide, and the observation group was treated with montelukast combined with glucocorticoid. The clinical effects of the two groups were compared after 3 months of treatment. Results There was no significant difference in the levels of Cys LTs and IL-5 between the two groups before treatment (P> 0.05). After treatment, the indexes in the observation group were significantly lower than those in the control group (P <0.05). The onset time and number of attacks in the observation group were significantly lower than those in the control group (P <0.05). There was no significant difference in cough, daytime symptoms and nocturnal symptom scores between the two groups (P> 0.05). After treatment, the observation group was significantly lower than the control group (P <0.05). Conclusion The treatment of chronic moderate bronchial asthma, montelukast combined with inhaled glucocorticoid treatment effect is significant, can make the clinical symptoms of children can be effectively improved, and promote the recovery of children.